Results 1 to 10 of about 2,252,561 (256)

Type 1 diabetes [PDF]

The Lancet, 2018
Type 1 diabetes is a chronic autoimmune disease characterised by insulin deficiency and resultant hyperglycaemia. Knowledge of type 1 diabetes has rapidly increased over the past 25 years, resulting in a broad understanding about many aspects of the ...
DiMeglio, Linda A., Evans-Molina, Carmella, Oram, Richard A.   +2 more
core   +7 more sources

Characterization of the functional and transcriptomic effects of pro-inflammatory cytokines on human EndoC-βH5 beta cells

Frontiers in Endocrinology, 2023
ObjectiveEndoC-βH5 is a newly established human beta-cell model which may be superior to previous model systems. Exposure of beta cells to pro-inflammatory cytokines is widely used when studying immune-mediated beta-cell failure in type 1 diabetes.
Caroline Frørup, Rebekka Gerwig, Cecilie Amalie Søndergaard Svane, Joana Mendes Lopes de Melo, Kristine Henriksen, Tina Fløyel, Flemming Pociot, Flemming Pociot, Simranjeet Kaur, Joachim Størling, Joachim Størling   +10 more
doaj   +1 more source

Pro-Inflammatory Cytokines Promote the Transcription of Circular RNAs in Human Pancreatic β Cells

Non-Coding RNA, 2022
Circular RNAs (circRNAs) have recently been implicated in impaired β-cell function in diabetes. Using microarray-based profiling of circRNAs in human EndoC-βH1 cells treated with pro-inflammatory cytokines, this study aimed to investigate the expression ...
Simranjeet Kaur, Caroline Frørup, Aashiq H. Mirza, Tina Fløyel, Reza Yarani, Maikel L. Colli, Jesper Johannesen, Joachim Størling, Decio L. Eizirik, Flemming Pociot   +9 more
doaj   +1 more source

Advances in Human Immune System Mouse Models for Personalized Treg-Based Immunotherapies

Frontiers in Immunology, 2021
Immunodeficient mice engrafted with a functional human immune system [Human immune system (HIS) mice] have paved the way to major advances for personalized medicine and translation of immune-based therapies.
Isabelle Serr, Isabelle Serr, Maria Kral, Maria Kral, Martin G. Scherm, Martin G. Scherm, Carolin Daniel, Carolin Daniel, Carolin Daniel   +8 more
doaj   +1 more source

Differences in lipid and blood pressure measurements between individuals with type 1 diabetes and the general population: a cross-sectional study

BMJ Open, 2023
Objectives Cardiovascular disease (CVD) is a precarious complication of type 1 diabetes (T1D). Alongside glycaemic control, lipid and blood pressure (BP) management are essential for the prevention of CVD.
Bruce H R Wolffenbuttel, Melanie M van der Klauw, Henk-Jan Aanstoot, Rita Delphine Maiko Varkevisser, Dick Mul   +4 more
doaj   +1 more source

Beta cell and immune cell interactions in autoimmune type 1 diabetes: How they meet and talk to each other

Molecular Metabolism, 2022
Background: The highly complex pathogenesis of Type 1 Diabetes is driven by several immune cell types with both effector and regulatory characteristics, which ultimately ends in the destruction of the insulin-producing beta cells.
Martin G. Scherm, Rebecca C. Wyatt, Isabelle Serr, David Anz, Sarah J. Richardson, Carolin Daniel   +5 more
doaj   +1 more source

Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT). [PDF]

, 2011
BACKGROUND: The prognosis for young people diagnosed with diabetes during childhood remains poor and this is mainly related to the long-term risk of developing vascular complications.Microalbuminuria identifies subjects at risk for diabetic nephropathy ...
Adolescent type 1 Diabetes cardio-renal Intervention Trial Research Group
core   +1 more source

Type 1 diabetes in children [PDF]

, 2013
Many children are not diagnosed early enough.
Kime, NH
core   +1 more source

Plasma Exosome-Enriched Extracellular Vesicles From Lactating Mothers With Type 1 Diabetes Contain Aberrant Levels of miRNAs During the Postpartum Period

Frontiers in Immunology, 2021
Type 1 diabetes is an immune-driven disease, where the insulin-producing beta cells from the pancreatic islets of Langerhans becomes target of immune-mediated destruction.
Caroline Frørup, Caroline Frørup, Aashiq H. Mirza, Aashiq H. Mirza, Reza Yarani, Lotte B. Nielsen, Elisabeth R. Mathiesen, Elisabeth R. Mathiesen, Peter Damm, Peter Damm, Peter Damm, Jens Svare, Christian Engelbrekt, Joachim Størling, Joachim Størling, Jesper Johannesen, Jesper Johannesen, Henrik B. Mortensen, Henrik B. Mortensen, Flemming Pociot, Flemming Pociot, Flemming Pociot, Simranjeet Kaur   +22 more
doaj   +1 more source

Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? [PDF]

, 2013
In this review, we explore the concept of ‘double diabetes’, a combination of type 1 diabetes with features of insulin resistance and type 2 diabetes.
A Caixas, AM Taylor, B Conway, B Teupe, B. M. Fisher, BF Voight, CT Prince, D Williams, D Yazici, DB Savage, DM Maahs, DM Maahs, DM Nathan, EA Nikkila, ER Christ, ES Kilpatrick, G Pambianco, G Perseghin, G Perseghin, G Roglic, G Ruotolo, H. M. Colhoun, HM Colhoun, IE Schauer, J Frystyk, J Guy, J Yip, J-L Selam, J. R. Petrie, JA Edge, JB Ferriss, JC Zgibor, JQ Purnell, JQ Purnell, JR Erbey, JR Petrie, JT Lahtela, KJ Nadeau, L Hodson, LM Thorn, M Kacerovsky, MR Taskinen, MR Taskinen, MR Taskinen, N Chaturvedi, N Sattar, N. Sattar, P Nevalainen, P Petruzzo, R Sinha, RA Heptulla, RW James, S Makimattila, S Norbert, S Vella, S. J. Cleland, SC Bain, SD Sibley, SJ Livingstone, SR Vethakkan, The Diabetes Control and Complications Trial Research Group, TJ Orchard, TJ Wilkin   +62 more
core   +3 more sources